NICE National Institute for Health and Care Excellence

NICE guidance

Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)

Technology appraisal guidance
Published: 7 May 2026

www.nice.org.uk/guidance/ta1154

Contents

Advice

NICE is unable to make a recommendation about the use in the NHS of oxybutynin hydrochloride (Vesoxx) for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida. Farco has confirmed that Vesoxx will not be launched in the UK for treating this indication, and therefore does not intend to make an evidence submission for the appraisal.

NICE will review the position if the company decides that it wants to make an evidence submission.

What this means in practice

Oxybutynin hydrochloride should not be routinely commissioned in the NHS in England for the condition and population stated in this terminated evaluation.

This is because an evidence submission was not provided, so NICE is unable to evaluate whether oxybutynin hydrochloride offers benefit and is value for money in this population.

If NHS organisations wish to consider oxybutynin hydrochloride for this indication, they should follow the advice on local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. These outline the approach that should be taken when there is no NICE guidance.

ISBN: 978-1-4731-9487-8